LAS VEGAS, NV -- December 17, 2024
-- InvestorsHub NewsWire -- Avant Technologies Inc. (OTCQB:
AVAI) ("Avant" or the "Company"), and its partner, Ainnova
Tech, Inc., (Ainnova) a leading healthcare technology company
focused on revolutionizing early disease detection using artificial
intelligence (AI), today announced Ainnova’s acquisition of an
exclusive license for 4 groundbreaking, AI-driven algorithms from
one of Asia’s most respected and largest healthcare
institutions. These solutions, validated across diverse
geographies, ethnicities, and socioeconomic populations with data
from over 2-million patients, will join Ainnova’s existing diabetic
retinopathy and retinal disease detection solutions.
The 4 algorithms include early
detection for cardiovascular risk, prediabetes and type 2 diabetes,
fatty liver disease, and chronic kidney disease. Combined with
Ainnova’s existing retinal disease detection tools, these new
algorithms will be used with Ainnova’s powerful cutting-edge AI
platform, VisionAI, to detect the early markers of these diseases
quickly and accurately by applying AI.
The acquisition of an exclusive
license to use 4 advanced algorithms in the Americas offers Ainova
Acquisition Corp. (AAC), the company formed by the partnership
between Avant and Ainnova, a robust platform for primary care
providers to streamline early risk screening and improving patient
care in the United States.
Ainnova will introduce these
cutting-edge solutions in Latin America with strategic partners in
primary healthcare services across key markets like Mexico and
Brazil. AAC expects to build on
Ainnova’s regional expansion by
securing clearance from the U.S. Food and Drug Administration in
2025 to then introduce these solutions in the U.S.
market.
While explaining that these efforts
aim to transform the current approach to preventive care by
providing accessible, efficient, and impactful health screening
solutions, Ainnova’s Chief Executive Officer, Vinicio Vargas, said,
"This license represents a pivotal moment for Ainnova and for its
partnership with Avant as it allows us to bring world class,
validated solutions to the Americas. This effort not only
complements our current solutions, but it also aligns with our
ongoing R&D initiatives to continue incorporating new diseases
that can be detected quickly and affordably, pushing the boundaries
of preventive care, and making healthcare more inclusive and
accessible to all."
The licensed algorithms enhance the
company’s capabilities to empower healthcare providers with
comprehensive, fast, and accessible tools for early disease
detection. Using simple patient datapoints - such as demographics,
lifestyle attributes, and routine measures, like blood pressure -
these algorithms enable rapid risk screening, facilitating timely
specialist referrals and improving health outcomes.
Key Features and Benefits
of the New Algorithms:
1. Cardiovascular Risk
Assessment:
-
- Accurately predicts coronary artery disease risk with over 90%
precision.
- Offers personalized recommendations through a Clinical Decision
Support System (CDSS), enabling targeted preventive
measures.
2. Prediabetes and Type 2 Diabetes
Prediction:
-
- Predicts the three-year risk of diabetes with an AUC of 0.861,
using demographic and lifestyle data.
- Provides tailored care plans and actionable insights to prevent
disease progression.
3. Liver Fibrosis
Screening:
-
- Identifies patients at risk of advanced liver fibrosis with
accuracy exceeding 88%.
- Supports timely referral and management of non-alcoholic fatty
liver disease.
4. Chronic Kidney Disease (CKD)
Monitoring:
-
- Predicts CKD progression and supports preventive interventions
to slow disease advancement.
- Guides care through integrated analysis of clinical and
laboratory data.
Mr. Vargas added, “This robust AI
platform marks a significant step toward global adoption, ensuring
that advanced AI tools are accessible to healthcare systems
everywhere.”
About Ainnova Tech,
Inc.
Ainnova is a Nevada-based
healthtech startup with headquarters in San Jose, Costa Rica, and
Houston, Texas. Founded by an experienced and innovative team that
is dedicated to leveraging artificial intelligence for early
disease detection. Recognized with multiple global awards and
renowned partnerships with hospitals and medical device companies,
we proudly introduce VisionAI – our cutting-edge platform designed
to prevent blindness and detect the early onset of diabetes.
Explore how Ainnova is revolutionizing healthcare through advanced
technology and proactive solutions.
About Avant Technologies
Inc.
Avant Technologies, Inc. is an
emerging technology company developing solutions in artificial
intelligence in healthcare. With a focus on pushing the boundaries
of what is possible in AI and machine learning, Avant serves a
diverse range of industries, driving progress and efficiency
through state-of-the-art technology.
More information about Avant can be
found at https://avanttechnologies.com
You can also follow us on social
media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking
Statements
Certain statements contained in
this press release may constitute “forward-looking
statements.” Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ
materially from those indicated by such forward-looking statements
because of various important factors as disclosed in our filings
with the Securities and Exchange Commission located at their
website (http://www.sec.gov). In
addition to these factors, actual future performance, outcomes, and
results may differ materially because of more general factors
including (without limitation) general industry and market
conditions and growth rates, economic conditions, governmental and
public policy changes, the Company’s ability to raise capital on
acceptable terms, if at all, the Company’s successful development
of its products and the integration into its existing products and
the commercial acceptance of the Company’s products. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect
to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
Avant Technologies (QB) (USOTC:AVAI)
過去 株価チャート
から 11 2024 まで 12 2024
Avant Technologies (QB) (USOTC:AVAI)
過去 株価チャート
から 12 2023 まで 12 2024
